Target intelligence / Profile preview

Poliovirus receptor (PVR) (PVR)

Target
PVR
Molecular classification
Immunoglobulin superfamily, Cell adhesion molecule, Nectin-like protein, Receptor, Type I transmembrane glycoprotein
01

Overview

Poliovirus receptor (PVR), also known as CD155, is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily and the nectin-like protein family (UniProt P15151). Originally identified as the primary entry receptor for poliovirus on host mucosal epithelial cells, it is now recognized as a pivotal immune checkpoint ligand in oncology. In healthy physiological states, CD155 is expressed at low levels and facilitates cell-cell adhesion at adherens junctions and mediates cell migration. In the context of cancer, CD155 is frequently overexpressed on tumor cells and antigen-presenting cells, where it interacts with the inhibitory receptors TIGIT and CD96 on T cells and natural killer (NK) cells to promote immune evasion (NIH). Conversely, it can bind the activating receptor DNAM-1 (CD226) to stimulate anti-tumor immunity, but this balance is often disrupted in the tumor microenvironment. Therapeutic development focuses on monoclonal antibodies like NTX-1088 and TGI-5 that directly target CD155, as well as engineered oncolytic polioviruses like lerapolturev that exploit CD155 for tumor-selective entry and lysis ( NCT05378425). Additionally, the CD155-TIGIT axis is a major target for a broad class of anti-TIGIT antibodies currently in clinical trials for various solid tumors.

Other names
CD155Nectin-like protein 5NECL-5HVEDPVSTage4PVR cell adhesion molecule
02

Mechanism of action

Directly blocking CD155 to prevent its interaction with inhibitory receptors TIGIT and CD96, thereby restoring T-cell and NK-cell mediated anti-tumor activity; utilizing CD155 as a portal for oncolytic viral entry and subsequent tumor cell lysis; and indirectly modulating the CD155 axis via TIGIT blockade to favor activating signals through DNAM-1.

03

Biological functions

Signal transductionImmune responseCell adhesionCell migrationViral entryAxonal transport
04

Disease associations

CancerInfectionNeurodegenerative diseaseInflammation
05

Safety considerations

Potential for immune-related adverse events (irAEs) due to checkpoint blockadeTheoretical risk of affecting normal cell adhesion and barrier function in mucosal tissuesRisk of neurotoxicity or off-target infection when using poliovirus-derived oncolytic agents
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

CD155 expression (IHC)Soluble CD155 (sCD155) levels in serumTIGIT expression on tumor-infiltrating lymphocytesDNAM-1 expression levels on effector cells

Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Poliovirus receptor (PVR) (PVR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poliovirus receptor (PVR) (PVR).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call